Endothelial progenitor cell numbers vary in newborns and adults; anti-gm-CSFα (CD116) antibody as a novel marker for EPC enumeration
Innate Immunity · 2026-04 · 32
DOI: 10.1177/17534259261438615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innate Immunity, online erschienen am 10.04.2026. Verfasst von Sevil Simsek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Erciyes University Medical Faculty, Kayseri, Türkiye. Hauptthemen laut MEDLINE: Endothelial Progenitor Cells, Granulocyte-Macrophage Colony-Stimulating Factor, Hematopoietic Stem Cells. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bilimsel Araştırma Projeleri, Erciyes Üniversitesi.
Abstract (Originalsprache)
Objective
Endothelial progenitor cells (EPCs) originate from hematopoietic stem cells and can be quantified in peripheral blood using flow cytometry. The anti-GM-CSFα antibody (CD116) may serve as a specific marker for EPC enumeration. This study aimed to quantify peripheral EPCs expressing CD116 and compare the results with other specific antibodies in newborns and adults. Materials and Methods EPC enumeration was performed by flow cytometric analysis of peripheral blood leukocytes (PBLs) obtained from 50 individuals, including 25 newborns and 25 adults. A CD34-specific antibody was used to identify hematopoietic stem/progenitor cells, while an antibody panel consisting of CD116, CD146, CD31, and CD45 was employed for EPC identification.
Results
Enumeration of CD34 + hematopoietic progenitor cells (HPCs) demonstrated that the mean CD34 + HPC count per 10 6 PBLs was 1643 (935–1458) in newborns and 242.7 (163–190) in adults, with a statistically significant difference between the groups ( p < 0.001). Using CD146 staining, the mean number of circulating EPCs per 10 6 PBLs was 94.2 (90.5–129.0) in newborns and 9.2 (7.4–12.4) in adults ( p < 0.001). Similarly, enumeration based on CD31 staining revealed mean EPC counts of 19.0 (12.5–28.0) in newborns and 6.0 (5.0–7.0) in adults ( p < 0.001). Enumeration using CD116 staining showed mean EPC numbers of 29.0 (23.0–34.0) in newborns and 3.0 (2.0–4.0) in adults, also indicating a significant difference between the two groups ( p < 0.001).
Conclusion
EPC numbers are significantly higher in newborns than in adults, suggesting an important developmental role for these cells. The GM-CSFα-specific antibody (CD116) may serve as a novel auxiliary marker for the identification and quantification of circulating EPCsubpopulations. Furthermore, EPC numbers appear to vary across different life stages, with higher numbers in newborns potentially reflecting the presence of a highly regenerative microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Erciyes University Medical Faculty, Kayseri, Türkiye.
- Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Türkiye.
- Department of Pediatric, İnönü University Medical Faculty, Malatya, Türkiye.
- Department of Pediatrics, Kayseri City Hospital, Neonatology, Kayseri, Türkiye.
ORCID-Profile: Sevil Simsek, Cagatay Karaca, Nezihe Koker, Mustafa Yavuz Koker
Förderung
- Bilimsel Araştırma Projeleri, Erciyes Üniversitesi
Zitieren
APA
Simsek, S., Karaca, C., Koker, N., Öztürk, A., & Koker, M. Y. (2026). Endothelial progenitor cell numbers vary in newborns and adults; anti-gm-CSFα (CD116) antibody as a novel marker for EPC enumeration. Innate Immunity, 32. https://doi.org/10.1177/17534259261438615
Vancouver
Simsek S, Karaca C, Koker N, Öztürk A, Koker MY. Endothelial progenitor cell numbers vary in newborns and adults; anti-gm-CSFα (CD116) antibody as a novel marker for EPC enumeration. Innate Immunity. 2026;32. doi:10.1177/17534259261438615
BibTeX
@article{Simsek2026,
author = {Simsek, Sevil and Karaca, Cagatay and Koker, Nezihe and Öztürk, Adnan and Koker, Mustafa Yavuz},
title = {Endothelial progenitor cell numbers vary in newborns and adults; anti-gm-CSFα (CD116) antibody as a novel marker for EPC enumeration},
journal = {Innate Immunity},
year = {2026},
volume = {32},
doi = {10.1177/17534259261438615}
}
EUVIMED